Interestingly, in a study analyzing the FDA database, the use of anti-PD-1 or PD-L1 antibodies was associated with the development of TB, whereas the use of anti-CTLA-4 antibodies did not increase the risk of developing TB [100]. Here, CTLA4 is linked to tuberculosis.